Mayo Clinic | Strategic Alliance Partners

June 19, 2023

Expert panelists open their discussion on diffuse large B-cell lymphoma by reflecting on diagnostic strategies and the frontline treatment armamentarium.

June 14, 2023

In this first episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, provide an overview on multicancer early detection tests and the need for randomized clinical trials to further explore their use.

May 25, 2023

Expert hematologist-oncologist Grzegorz Nowakowski, MD, reviews data from the 5-year analysis of the L-MIND study combining tafasitamab with lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.

May 24, 2023

Before sharing clinical pearls for the treatment of prostate cancer, key opinion leaders reflect on the potential use of immune checkpoint inhibitors in mCRPC.

May 24, 2023

Expert panelists consider the real-world application of PARP inhibitor data in patients with metastatic castration-resistant prostate cancer.

May 19, 2023

Morie A. Gertz, MD, discusses the limitations of the current Mayo Stage IV amyloidosis treatment landscape, the rationale for investigating birtamimab in this population, and the importance of raising awareness for the AFFIRM-AL trial.

May 17, 2023

Morie A. Gertz, MD, discusses the rationale for the phase 3 AFFIRM-AL trial in patients with amyloid light chain amyloidosis and elaborates on the challenges that may arise when enrolling patients to this trial.

May 17, 2023

Lida A. Mina, MD, discusses the evolution of the antibody-drug conjugates fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine in HER2-positive breast cancer.

May 17, 2023

Lida A. Mina, MD, discusses the evolving role of ADCs across breast cancer subtypes, current data on the use of CDK4/6 inhibitors in HR-positive, HER2-negative breast cancer, and the increased use of genomic testing and NGS to improve the sequencing of agents in triple-negative breast cancer.

May 17, 2023

Comprehensive insight on the evolving role of PARP inhibitors in metastatic castration-resistant prostate cancer and clinical trials in this setting.

May 17, 2023

Expert oncologists briefly review the current treatment paradigm of metastatic castration-resistant prostate cancer (mCRPC).

May 16, 2023

Thomas M. Habermann, MD, discusses ongoing clinical trials in mantle cell lymphoma and marginal zone lymphoma.

May 16, 2023

Thomas M. Habermann, MD, expands on previous data that supported the initial accelerated approval of ibrutinib in marginal zone lymphoma and mantle cell lymphoma, phase 3 data leading to the agent’s voluntary withdrawal, and investigations of ibrutinib and other BTK inhibitors that could significantly change the treatment landscape in mantle cell lymphoma and marginal zone lymphoma.

May 16, 2023

Thomas M. Habermann, MD, discusses the data that led to the decision to withdraw the indication for ibrutinib for the treatment of patients with mantle cell lymphoma.

May 11, 2023

Karen S. Anderson, MD, PhD, discusses novel and emerging therapies, as well as potential future targets, for the treatment of patients with hormone receptor–positive breast cancer.

May 10, 2023

Closing out their segment on metastatic hormone-sensitive prostate cancer, panelists review other treatment modalities being investigated in clinical trials.

May 10, 2023

Expert insight on methods to educate patients on available treatment options in the setting of metastatic hormone-sensitive prostate cancer.

May 09, 2023

Karen S. Anderson, MD, PhD, discusses the evolution of antibody-drug conjugates in the treatment of different subgroups of patients with metastatic breast cancer.

May 08, 2023

Thomas M. Habermann, MD, discusses the evolving treatment landscape of mantle cell lymphoma.

May 08, 2023

Karen S. Anderson, MD, PhD, discusses emerging data and role for CDK4/6 inhibitors in the treatment of patients with hormone receptor–positive, HER2-negative breast cancer, along with the growing use of antibody-drug conjugates across the breast cancer spectrum and updates in triple-negative breast cancer.